Canaccord Genuity Downgrades Chembio Diagnostics (CEMI) to Hold as FDA Revoked EUA
Tweet Send to a Friend
Canaccord Genuity analyst Max Masucci downgraded Chembio Diagnostics (NASDAQ: CEMI) from Buy to Hold with a price target of $7.00.The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
